PT  - JOURNAL ARTICLE
AU  - Amorim, Gustavo
AU  - Haas, David W.
AU  - Cordeiro-Santos, Marcelo
AU  - Kritski, Afrânio L.
AU  - Figueiredo, Marina C.
AU  - Staats, Cody
AU  - Hachey, Brian
AU  - Turner, Megan
AU  - Andrade, Bruno B.
AU  - Rolla, Valeria C.
AU  - Sterling, Timothy R.
AU - the Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network
TI  - Estimating optimal therapeutic drug levels of anti-tuberculosis medications based on treatment safety and effectiveness
AID  - 10.1101/2024.08.30.24312723
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.30.24312723
4099  - http://medrxiv.org/content/early/2024/08/31/2024.08.30.24312723.short
4100  - http://medrxiv.org/content/early/2024/08/31/2024.08.30.24312723.full
AB  - Background Therapeutic drug ranges (TDR) for standard anti-tuberculosis (TB) treatment have been determined based on expected drug levels at least 2 hours after taking the dose. In this study we constructed TDR for TB drug levels based on minimizing drug toxicity and maximizing treatment effectiveness.Methods Participants were followed prospectively in the Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil observational cohort study. We focused on participants with culture-confirmed drug-susceptible pulmonary TB who underwent standard TB therapy. TDR were estimated for each TB drug separately: isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide (PZA). TDR were defined as drug concentrations that were both safe and effective: safety was defined as the probability of having an ADR of at most 5%, while effectiveness was defined as a probability of at least 95% of not having either TB treatment failure or recurrence.Results There were 765 plasma samples from 448 patients; 110 (24.6%) were people with HIV, 9 (2.0%) had a grade 3 or higher ADR, and 15 (3.3%) had treatment failure/recurrence. Higher drug concentrations of INH, RIF and EMB were associated with increased odds of having ADR. High concentrations of INH suggested protection against treatment failure/recurrence. Estimated therapeutic drug range for INH (2.3-8.2 µg/ml) and for RIF (0.5-7.5 µg/ml) differed from the currently recommended drug ranges (3-5 µg/ml and 8-24 µg/ml, respectively). Estimates for PZA and EMB were similar to the currently recommended values.Conclusions Our estimated upper end TDR were higher for INH and lower for RIF compared to currently recommended ranges.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Departamento de Ciência e Tecnologia; Secretaria de Ciência e Tecnologia; Ministério da Saúde, Brazil (25029.000507/2013-07); National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (U01 AI069923, R01 A1120790, R01 AI077505, P30 AI110527)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The RePORT-Brazil study was approved by the institutional review board of the Instituto Nacional de Infectologia Evandro Chagas (CAAE: 25102412.3.1001.5262), by the institutional review boards of the other study sites, and Vanderbilt University Medical Center. Written informed consent was obtained from all participants and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors